Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 1 - BKM120 for Patients With PI3K-activated Tumors

Trial Profile

Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 1 - BKM120 for Patients With PI3K-activated Tumors

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs Buparlisib (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Therapeutic Use
  • Acronyms SIGNATURE
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 07 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 01 Aug 2016 Planned End Date changed from 1 May 2016 to 1 May 2017.
    • 01 Aug 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top